LipidBrick® IM21.7c is a novel cationic lipid dedicated to the formulation of lipid nanoparticles (LNPs) for the development of mRNA-based vaccines and therapeutics. LipidBrick® IM21.7c overcomes the challenges posed by the current generation of ionizable lipids used in LNPs, allowing for wider in vivo biodistribution and reduced accumulation in the liver. Proof-of-concept work has demonstrated that the intrinsic properties of LipidBrick® IM21.7c in modulating the overall electrical charge of LNPs extend the in vivo biodistribution and improve both drug efficacy and formulation stability without inducing safety concerns.

• Efficient: Modulate LNP properties to adapt the biodistribution depending on the therapeutic purpose
• Secure: Use a unique lipid structure protected by an independent patent owned by Polyplus®
• Accelerate your project: in vitro and in vivo proof of concept have been successfully performed
• Colored

Formula: C₅₉H₁₁₇ClN₂
Molecular weight: 890.03
Synonyms: LipidBrick ; IM21.7c
GHS Symbol(s): GHS07
GHS Signal Word: Warning

Classification according to Regulation (EC) No 1272/2008: Acute toxicity, Oral (Category 4), H302, H312, H332.
Skin Irrit. (Category 2), H315.
Eye Irrit. (Category 2), H319.
Specific target organ toxicity, single exposure;Respiratory system (Category 3), H335.

Color: White to off-white.
Identity: Conform to reference spectra.